Endometrial Cancer Clinical Trial
Official title:
Telephone Follow-up After Treatment for Endometrial Cancer.
The aim of this study is to investigate the feasibility, safety and accuracy of a telephone
follow-up for women previously treatment for endometrial cancer.
To achieve this aim, potentially eligible women attending the Queensland Centre for
Gynaecological Cancer (QCGC) outpatient clinic for review following previous treatment for
endometrial cancer will be recruited by this study. The study aims to recruit all new
patients as well as all patients who return to QCGC for their follow-up and who had treatment
within the previous 2 years.
The proposed project will involve generation of an evidence-based checklist of signs and
symptoms of disease recurrence from a thorough literature review. The generated symptom
checklist will be pilot tested and the refined symptom checklist will be used to follow study
participants over a period of 12 months.
During the follow-up period, the basic standard of follow-up after primary treatment for
endometrial cancer at the QCGC, Royal Brisbane and Women's Hospital (RBWH)will not be
altered; however, the study participants will be interview via telephone 2 to 5 days prior to
their scheduled review dates.
The main outcome measure will be the estimated recurrence rate as derived from the telephone
assessment and this will be compared to the clinically detected recurrences as recorded in
patients' medical files.
It is hypothesized, that the telephone follow-up will identify 90% of all recurrences
correctly that are later confirmed during the clinical follow-up.
In addition to the main outcome, we will also assess patients' satisfaction with each of the
follow-up programs, whether or not lifestyle behaviours were queried and support offered to
improve wellbeing.
The focus of the study is;
1. To generate an evidence-based checklist of signs and symptoms of recurrence of
endometrial cancer.
2. To assess the sensitivity and specificity of a telephone follow-up compared to the
current clinic-based follow-up in the detection of recurrence of endometrial cancer.
3. To determine patients' satisfaction with the clinic and telephone follow-up.
4. To assess patients' self reported well being (physical activity, smoking, diet, anxiety,
depression and quality of life).
The proposed project will involve generation of an evidence-based checklist of signs and
symptoms of recurrence. The generated symptom checklist will be used to follow study
participants over a period of 12 months.
During the follow-up period, patients' routine clinic follow-up schedules will not be
altered, however; the study participants will be interviewed via telephone 2 to 5 days prior
to their scheduled clinic visits dates. The checklist of signs and symptoms generated by this
study will form the basis for this interview.
In addition, we will also enquire about the participant's wellbeing and provide resources on
physical activity, diet and other life style behaviours and supportive care when needed.
The data analysis will include determining:
i. Sensitivity- Proportion of those with the condition who have a positive test.
ii. Specificity-Proportion of those without the condition who have a negative test.
iii. Positive predictive value (PV+) - Proportion of those with a positive test who have the
condition.
iv. Negative predictive value (PV-) - Proportion of those with a negative test who do not
have the condition.
Overall accuracy of the symptom checklist compared to the clinic-based follow-up program will
also be calculated.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05796518 -
Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors
|
N/A | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06463028 -
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, Serabelisib With Paclitaxel, and Paclitaxel Alone in Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT03820024 -
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
|
N/A | |
Active, not recruiting |
NCT05082025 -
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
|
Phase 2 | |
Active, not recruiting |
NCT00587886 -
Estrogen, Diet, Genetics and Endometrial Cancer
|
||
Completed |
NCT05378152 -
Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity
|
N/A | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Recruiting |
NCT04569773 -
Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Not yet recruiting |
NCT06073184 -
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium
|
Phase 2 | |
Not yet recruiting |
NCT05998798 -
Revealing Engagement Patterns Among Endometrial Cancer Patients
|
||
Not yet recruiting |
NCT06366347 -
ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab
|
Phase 2 | |
Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
Completed |
NCT02549989 -
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
|
Phase 2 |